Multiple tumors in patients with pancreatic neuroendocrine tumours: morphological and immunohistochemical characteristics Abstract #61

Introduction: Pancreatic islet cell tumors occur in 80% of patients with MEN 1. Tumors are often multicentric. They often produce multiple peptides and biogenic amines.
Aim(s): Improve immunophenotyping of multiple pancreatic neuroendocrne tumors.
Materials and methods: Immunophenotyping of the removed pancreatic neuroendocrine tumors (PNET) of 268 patients aged from 9 to 80 years old was carried out. MEN 1 syndrome was determined in 29 patients (10,8%). The neuroendocrine markers (chromogranin A, synaptophysin, CD56) and the hormones insulin, proinsulin, glucagon, somatostatin, gastrin, pancreatic polypeptide, serotonin, ACTH were used.
Conference: 7th Annual ENETS Conference (2010)
Category: Basic
Presenting Author: Prof Larisa Gurevich

To read results and conclusion, please login ...

Further abstracts you may be interested in

#50 Clinical-morphology correlation in diagnostics and evaluating surgery results of pancreatic insulinoma and nesidiobastosis
Introduction: Organic hyperinsulinism syndrome (OHS) is revealed in 85% cases of pancreas insulinoma. Nesidioblastosis (NB) induces OHS in 15% of the cases. Surgical cure provides all symptoms of insulinoma disappearing, while cytoreductive operation results in considerable improvement of life quality. There is no intraoperative opportunity to reveal insulinoma grade, even if an urgent biopsy is performed. Thus, it is essential to determine the cause of OHS and to apply the surgical cure method during the preoperational period, thereby improving the long-term prognosis.
Conference: 7th Annual ENETS Conference (2010)
Category: Basic
Presenting Author: Dr. Evelina Askenderova
#106 Gastroenteropancreatic neuroendocrine tumors: single institution clinicopathological study
Introduction: Neuroendocrine cells are widely distributed throughout the body, and neoplasms from these dispersed cells can arise at many sites. They are distinguished into two broad categories: 1) Tumors identified as small cell lung carcinomas with biology and natural history of a high-grade malignancy and characteristics of small cell undifferentiated or anaplastic appearance by light microscopy. The WHO categorizes these tumors as poorly-differentiated neuroendocrine carcinomas; 2) Well-defined neuroendocrine tumors (NETs) with variable, but most lyindolent biologic behavior and characteristic well-differentiated histologic features. The majority arise in the gastrointestinal tract and collectively they are referred as gastroenteropancreatic neuroendocrine tumors (GEP/NETs). They include carcinoid tumors, pancreatic islet cell tumors (gastrinoma, insulinoma, glucagonoma, VIPoma, somatostatinoma), paragangliomas, pheochromocytomas, and medullary thyroid carcinomas. The WHO classifies the GEP/NETs as well-differentiated NETs (carcinoid tumors) if they are noninvasive and have benign behavior or uncertain malignant potential. In contrast, GEP/NETs with characteristics of low-grade malignancy with invasion of the muscularis propria or beyond, or metastases, are characterized as well-differentiated neuroendocrine carcinomas (malignant carcinoids). Pancreatic islet cell tumors, whether functioning or not, are classified as well-differentiated NETs or well-differentiated neuroendocrine carcinomas, due to the (depending on) histologic characteristics. The WHO classification for gastroenteropancreatic NETs based on stage (ie size and presence of metastases) and grade (mitotic rate, perineural and lymphovascular invasion, Ki-67 proliferative index) categorizes them as well-differentiated NETs, e.g., carcinoid tumors, or as well-differentiated neuroendocrine carcinomas.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Michael M. Vaslamatzis
#240 Glycodelin Expression in Pancreatic Neuroendocrine and Solid-Pseudopapillary Tumors as in Important Factor of Favorable Disease Prognosis
Introduction: Glycodelin (GD) is a multifunctional highly glycosylated protein, expressed in hormone-dependent human tissues and tumors. GD participates in apoptosis regulation and inter-cellular adhesion.
Conference: 8th Annual ENETS Conference (2011)
Category: Basic
Presenting Author: Larissa Gurevich
#348 Management of Multiple Endocrine Neoplasia Type 1 in Patients with Pancreatic Neuroendocrine Tumors
Introduction: Screening for MEN-1 is an integral part of examination of patients with pNETs because revelation of this hereditary pathology radically influences tactics of treatment.
Conference:
Category: Basic
Presenting Author: Ivan Vasiliev
#827 Neuroendocrine Tumors of the Pancreas Grade 2 with Ki-67 Index More Than 5% and with Expression Cytokeratin 19 are the Risk Group of Rapid Progression
Introduction: Cytokeratin 19 (CK19) is the marker of pluripotent cells of the epithelium of the pancreatic ducts, which is not detected in differentiated endocrine cells. Our experience shows that many patients with neuroendocrine tumors of the pancreas (pNET) G2 have a rapid progression of the disease a few years after diagnosis, and metastases are found most commonly in the liver.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Pathology, grading, staging
Presenting Author: MD Larisa Gurevich